ETOP IBCSG Partners Foundation — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

3 Recruiting

6 Completed trials

14 Countries active

20 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 7

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 5 Non-small cell lung cancer stage IIIA 2 Small cell lung cancer extensive stage 2 Small cell lung cancer 2 Non-small cell lung cancer stage III 2 Non-small cell lung cancer stage II 2 Non-small cell lung cancer stage IIIB 1 Breast cancer recurrent 1 Non-small cell lung cancer metastatic 1 Hormone receptor positive breast cancer 1 PD-L1 positive cancer 1 HER2 negative breast cancer 1

Top IMPs

DURVALUMAB 4 ADAGRASIB 1 AMIVANTAMAB 1 ANASTROZOLE 1 ATEZOLIZUMAB 1 BEVACIZUMAB 1 BRIGATINIB 1 CEMIPLIMAB 1 GIREDESTRANT 1 LAZERTINIB 1 NIRAPARIB TOSILATE MONOHYDRATE 1 PALBOCICLIB 1

All trials

10 total

A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has … Pending

2025-522288-13-00 Phase II 4 countries TARLATAMAB
A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca… Recruiting

2024-519901-36-00 Phase III 7 countries CEMIPLIMAB
A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non-… Recruiting

2023-508773-82-00 Phase III 7 countries DURVALUMAB
A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF… Recruiting

2022-502092-33-00 Phase II 5 countries ATEZOLIZUMAB; DURVALUMAB; NIRAPARIB TOSILATE MONOHYDRATE
ETOP 14-18 CHESS: Immunotherapy, chemotherapy and radiotherapy, followed by surgery or radiotherapy, for patients with newly diagnosed non-s… Ended

2024-511134-12-00 Phase II 3 countries DURVALUMAB; TREMELIMUMAB
ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw… Ended

2023-510463-35-00 Phase II 5 countries ADAGRASIB
ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w… Ended

2024-512288-29-00 Phase II 4 countries AMIVANTAMAB; BEVACIZUMAB; LAZERTINIB
Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended

2024-510776-20-00 Phase III 5 countries PALBOCICLIB
A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te… Ended

2022-502467-38-00 Phase II 4 countries BRIGATINIB; DURVALUMAB
A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended

2022-503013-32-00 Phase II 7 countries ANASTROZOLE; GIREDESTRANT; TRIPTORELIN

Showing 1–10 of 10 trials

← All sponsors A–Z